Biomedicine · global
More Stable T-Cell Receptor Pairing: Computational Design Boosts Anticancer and Antiviral Responses
Researchers modified the shared framework of T-cell receptors to help engineered immune cells recognize and attack targets more effectively. Six receptors and mouse experiments showed preliminary results, but whether the approach can be used safely in humans remains to be verified.
Teaching immune cells to recognize cancer does not necessarily enable them to attack it effectively. Receptors introduced into cells must be stably displayed on the surface, and the protein chains that make up those receptors must pair correctly. An Israeli research team applied computational design to this easily overlooked step, improving receptor structure and enabling engineered T cells to demonstrate stronger attack capabilities in early experiments.
The collaborative study by Bar-Ilan University and the Weizmann Institute of Science was published in *Science Advances*. The team focused on T-cell receptors (TCRs), which recognize protein fragments presented by other cells and help the immune system detect abnormalities. However, after a new TCR is introduced, its protein chains may incorrectly pair with chains from the cell’s existing receptors, reducing the surface expression of functional receptors and potentially creating unintended recognition capabilities.
The researchers used two protein design algorithms, PROSS and FuncLib, to modify the constant regions of human TCRs—the structural parts shared by different receptors. The goal was to improve stability and make the two introduced chains more likely to pair with each other. After multiple rounds of experimental screening, the team selected a version called a “structurally enhanced TCR” (SET). Designs proposed by the computer still had to be evaluated in cell experiments to determine whether they were genuinely useful.
According to the paper’s abstract provided by the Weizmann Institute of Science, SET reduced incorrect pairing, increased receptor surface expression, and strengthened the overall functional response of T cells to their targets. Cells carrying SET secreted more cytokines and also showed increased activation and killing ability. These improvements were reproduced across six different TCRs, providing preliminary evidence across receptors for modifying the shared framework, but this does not yet establish that all TCRs would benefit.
A report provided by Bar-Ilan University and published in Medical Xpress further stated that testing covered cancer-related targets as well as viral targets from Epstein-Barr virus and SARS-CoV-2, with stronger immune activity observed in each case. This suggests that the same structural modifications may be applicable to different recognition tasks, but cellular responses to viral targets do not constitute proof that the approach can treat infected people.
In experiments involving mice bearing human tumors, the report stated that on day 83, tumors in the group receiving SET-engineered T cells were approximately 35% smaller than those in the untreated control group. By day 127, all mice receiving the enhanced cells were alive, compared with fewer than half in the control group. These figures show a signal of tumor control in an animal model, but the comparison was with untreated controls, so the 35% cannot be interpreted as an additional therapeutic benefit relative to the original receptor. The report also did not specify the number of animals in each group.
The appeal of this work lies in focusing improvements on a structure shared by multiple receptors, potentially reducing the work needed to optimize candidate receptors individually in the future. However, the existing evidence still comes from laboratory experiments and animal models. Reducing incorrect pairing is only one part of safety assessment. Further research is needed to determine whether stronger immune responses are accompanied by unintended attacks or toxicity, and whether the effects can be sustained in human disease.